AIM Investors

Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections

By August 14, 2018No Comments

Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections

https://www.motifbio.com/wp-content/uploads/2018/08/MTFB-FDA-acceptance-of-NDA-14.08.18-1.pdf